Effects of ursodeoxycholic acid on statin-induced impaired glucose tolerance: study protocol for a randomized controlled trial Authors: Yue Yu, Jie Zheng, Jianqing She, Zuyi Yuan, Yue Wu Published: 2026 ABSTRACT AbstractIntroductionStatin therapy is associated with an increased risk of dysglycaemia and new-onset type 2 diabetes, which compromises patient adherence. Ursodeoxycholic acid (UDCA), a hepatoprotective drug, has shown potential for improving glycaemic control, but its role in preventing statin-induced dysglycaemia remains unexplored in prospective randomised trials, particularly in a primary prevention setting. This trial aims to determine whether UDCA coadministration can prevent statin-induced impairment of glucose tolerance.Methods and analysisThis is an investigator-initiated, prospective, double-blind, randomised, placebo-controlled trial. A total of 128 participants with newly diagnosed hyperlipidaemia and no history of diabetes or cardiovascular events will be enrolled. Participants will be randomly assigned (1:1) to receive either atorvastatin (20 mg/day) plus UDCA (500 mg/day) or atorvastatin plus a matching placebo for 180 days. The primary outcome is the difference in glycated haemoglobin (HbA1c) absolute change from baseline to Day 180 between the intervention and control groups. The secondary outcomes are the difference in the absolute change of cardiometabolic risk factors and body composition between the intervention and control groups from baseline to Day 180. Safety outcomes include adverse events, serious adverse events, abnormal vital signs and abnormal laboratory parameters from baseline to Day 180. Data will be analysed according to the ITT principle.Ethics and disseminationThis study has been approved by the Ethics Committee of the First Affiliated Hospital of Xi'an Jiaotong University (No. XJTU1AF2023LSK-149-02). The study findings will be disseminated through peer-reviewed journals, symposiums and conference presentations.Trial registration numberNCT06684106.Keywords: Cardiovascular Disease, Primary Prevention, CARDIOLOGY, Body Mass Index STRENGTHS AND LIMITATIONS OF THIS STUDY Recruiting statin-naive participants with newly diagnosed hyperlipidaemia limits confounding from previous lipid-lowering therapy. Recruiting statin-naive participants with newly diagnosed hyperlipidaemia limits confounding from previous lipid-lowering therapy. The double-blind, placebo-controlled randomised design minimises performance and detection bias. The double-blind, placebo-controlled randomised design minimises performance and detection bias. Repeated follow-up visits over 180 days allow standardised assessment of glycaemic, lipid, body composition and safety outcomes. Repeated follow-up visits over 180 days allow standardised assessment of glycaemic, lipid, body composition and safety outcomes. The single-centre design and modest sample size may limit generalisability. The single-centre design and modest sample size may limit generalisability. The absence of oral glucose tolerance test (OGTT), mixed-meal testing or serial measurements of insulin or glucagon-like peptide-1 may limit the interpretation of dynamic metabolic responses. The absence of oral glucose tolerance test (OGTT), mixed-meal testing or serial measurements of insulin or glucagon-like peptide-1 may limit the interpretation of dynamic metabolic responses. Introduction Atherosclerotic cardiovascular disease (ASCVD) is a multifactorial disorder driven by an interplay of genetic predisposition and environmental exposures.1 2 In recent years, the rising incidence and mortality of ASCVD have posed a severe public health threat, establishing it as a major and growing challenge both in China and globally.3 4 Current guidelines widely acknowledge statin therapy as the cornerstone for preventing major adverse cardiovascular events in patients with ASCVD.5 However, statin use has also been associated with an increased risk of long-term impaired glucose tolerance and new-onset type 2 diabetes, raising considerable clinical concern.6–8 A meta-analysis found that fasting glucose levels showed an elevation of 0.04 mmol/L with both low- to moderate-intensity (95% CI 0.03 to 0.05) and high-intensity statins (0.02 to 0.06), among non-diabetic participants at baseline. Similarly, HbA1c increased by 0.06% (0.00 to 0.12) in the low- to moderate-intensity statin group and by 0.08% (0.07 to 0.09) in the high-intensity group.8 There is a compelling need for further research to identify effective strategies that mitigate statin-induced dysglycaemic effects without compromising their cardiovascular benefits, thereby optimising the overall risk-benefit profile and therapeutic value for ASCVD patients. Ursodeoxycholic acid (UDCA) is a well-established therapeutic agent widely used in clinical practice for autoimmune liver diseases such as primary biliary cholangitis and primary sclerosing cholangitis.9 10 Furthermore, a number of randomised controlled trials have indicated that UDCA also offers therapeutic benefits in individuals with metabolic dysfunction-associated steatotic liver disease, not only improving liver function but also contributing to better glycaemic control.11–13 Interestingly, the metabolic benefits of UDCA may be particularly relevant to statin-induced dysglycaemia, based on emerging insights into its mechanism of action. The potential protective effect of UDCA may be related to its ability to modulate bile acid metabolism and gut microbiota-related bile acid signalling. Previous studies suggested that UDCA may modulate the bile acid profile and gut microbiota-related bile acid metabolism and promote glucagon-like peptide-1 (GLP-1) secretion through Takeda G protein-coupled receptor 5 (TGR5)-related signalling.14 15 In addition, alterations in bile acid composition may influence the entero-pancreatic endocrine axis, including GLP-1, GIP and insulin secretion.16 Furthermore, a pilot study demonstrated that in patients who exhibited a significant increase in glycated haemoglobin (HbA1c) after more than 6 months of statin treatment, UDCA supplementation for 8 weeks significantly reduced HbA1c and increased GLP-1 levels, while also improving liver function parameters.14 Currently, no prospective randomised controlled trials have been conducted to explore strategies for preventing statin-induced impaired glucose tolerance in patients with newly diagnosed hyperlipidaemia. Therefore, a randomised controlled study is warranted to evaluate the efficacy of a novel combination therapy comprising statins and UDCA in improving glycaemic parameters without compromising the lipid-lowering and cardiovascular benefits of statin therapy, while also assessing its feasibility as a potential therapeutic strategy. The overall aim of this study is to evaluate the efficacy and safety of a novel combination therapy—atorvastatin plus UDCA—in patients with newly diagnosed hyperlipidaemia. This trial aims to determine whether the addition of UDCA can ameliorate statin-induced impaired glucose tolerance without compromising the lipid-lowering and cardiovascular benefits of atorvastatin. Methods Study design This study is an investigator-initiated, single-centre, prospective, double-blind, randomised, placebo-controlled trial. This trial will be conducted at the First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China. This study focuses primarily on patients with newly diagnosed hyperlipidaemia who are stratified as moderate to high risk (and thus eligible for lipid-lowering therapy per clinical guidelines) based on their ASCVD risk score, with no prior history of such treatment. According to current lipid-management guidelines17 18 and for the purposes of this trial, hyperlipidaemia is defined as a fasting low-density lipoprotein cholesterol (LDL-C) level ≥3.4 mmol/L (130 mg/dL) in adults. LDL-C is used as the only lipid-related eligibility criterion, because it is the principal treatment target for initiating statin therapy in current lipid-management guidelines. The primary objective of this study is to verify the efficacy of combination therapy with UDCA vs atorvastatin plus placebo in reducing HbA1c levels from baseline to Day 180, under the premise of a consistent atorvastatin administration regimen. Recruitment, screening and follow-up Participants will be recruited from the First Affiliated Hospital of Xi’an Jiaotong University and neighbouring communities through posters and WeChat-based promotion. The recruitment materials will provide a brief overview of the study and contact information for the study team. Individuals who contact the study team in response to the recruitment materials will undergo an initial eligibility assessment by trained investigators. This trial will use consecutive recruitment of potentially eligible participants rather than population-based random sampling. Potentially eligible individuals will then be invited to attend a screening visit, during which investigators will assess eligibility according to the predefined inclusion and exclusion criteria, including lipid profile, HbA1c, liver and renal function, vital signs, medical history and concomitant medications. Eligible participants will receive a detailed explanation of the study, and written informed consent will be obtained before formal enrolment. Recruitment will continue until the prespecified sample size of 128 randomised participants is reached. A sample participant consent form is provided as online supplemental file 1. The study consists of a 14-day screening period followed by an 180-day follow-up phase (figure 1 and table 1). During the screening phase, investigators will conduct eligibility assessments based on a comprehensive review of participants’ vital signs, physical examination findings, laboratory test results and concomitant medications. Laboratory tests include a blood lipid profile, HbA1c, aspartate aminotransferase (AST), alanine aminotransferase (ALT) and serum creatinine. Additionally, laboratory test results obtained within 4 weeks prior to study enrolment may be used for eligibility evaluation. Study flow diagram. ITT, intention-to-treat; PP, per-protocol; UDCA, ursodeoxycholic acid. Table 1Schedule of enrolment, randomisation, follow-up, and assessmentsStudy periodScreeningRandomisationDouble-blind follow-upVisitScreeningBaselineVisit 1Visit 2Visit 3Study day−14040110180Visit window----±7 days±7 days±12 daysInformed consentXEligibility criteriaXXDemographicsXMedical history/medication historyXConcomitant medicationXXXXXRandomisationXBlood pressureXXXXHbA1cXXXXOther glycaemic parameters*XXXXBody composition†XXXXLipid profile‡XXXXBiochemical parameters§XXXXTreatment compliance assessmentXXXAdverse eventsXXXXSerious adverse eventsXXXX*Other glycaemic parameters include fasting glucose, fasting insulin, fasting C-peptide, HOMA-IR, fasting serum total GLP-1 and 2-hour postprandial plasma glucose. The 2-hour postprandial plasma glucose assessment will be performed at baseline and Visit 3 only in participants who consent to this assessment at baseline.4†Body composition parameters include height, body weight, fat-free mass, body fat mass, muscle mass, visceral fat area, waist circumference, BMI, and fat-free mass index.‡Lipid profile includes total cholesterol, LDL-C, HDL-C, triglycerides, and Lp(a).§Biochemical and laboratory parameters include alanine aminotransferase, aspartate aminotransferase, creatine kinase, complete blood count, and high-sensitivity C-reactive protein.BMI, body mass index; GLP-1, glucagon-like peptide-1; HDL-C, high-density lipoprotein cholesterol; HOMA-IR, Homeostatic Model Assessment of Insulin Resistance; LDL-C, low-density lipoprotein cholesterol; Lp(a), lipoprotein(a). Schedule of enrolment, randomisation, follow-up, and assessments Other glycaemic parameters include fasting glucose, fasting insulin, fasting C-peptide, HOMA-IR, fasting serum total GLP-1 and 2-hour postprandial plasma glucose. The 2-hour postprandial plasma glucose assessment will be performed at baseline and Visit 3 only in participants who consent to this assessment at baseline.4 Body composition parameters include height, body weight, fat-free mass, body fat mass, muscle mass, visceral fat area, waist circumference, BMI, and fat-free mass index. Lipid profile includes total cholesterol, LDL-C, HDL-C, triglycerides, and Lp(a). Biochemical and laboratory parameters include alanine aminotransferase, aspartate aminotransferase, creatine kinase, complete blood count, and high-sensitivity C-reactive protein. BMI, body mass index; GLP-1, glucagon-like peptide-1; HDL-C, high-density lipoprotein cholesterol; HOMA-IR, Homeostatic Model Assessment of Insulin Resistance; LDL-C, low-density lipoprotein cholesterol; Lp(a), lipoprotein(a). Follow-up visits will be conducted on Day 40, Day 110, and Day 180. At each follow-up visit, participants will undergo the same physical examination, laboratory tests and body composition analysis. At each follow-up visit, participants will receive CNY 100 as travel reimbursement. Laboratory tests include fasting glucose, fasting insulin, fasting C-peptide, Homeostatic Model Assessment of Insulin Resistance (HOMA-IR) and fasting serum total GLP-1. A lipid profile includes total cholesterol, triglycerides, high-density lipoprotein cholesterol (HDL-C), LDL-C and lipoprotein(a) [Lp(a)]. Other biomarkers include ALT, AST, creatine kinase (CK) and high-sensitivity C-reactive protein (hs-CRP). Body composition includes body weight, body fat mass, muscle mass and visceral fat area. Serious adverse events (SAEs) and adverse events (AEs) will be recorded at each visit. For GLP-1 measurement, fasting blood samples will be collected in the morning after an overnight fast. Serum samples will be obtained using standard clinical serum collection tubes and stored at −80 °C until analysis, with repeated freeze-thaw cycles avoided. Fasting serum total GLP-1 will be measured using a validated commercial total GLP-1 assay according to the manufacturer’s instructions. Total GLP-1 reflects overall GLP-1-related peptide levels, including intact GLP-1 and its major metabolites, rather than circulating biologically active GLP-1 alone. Therefore, GLP-1 results in this study will be interpreted as fasting serum total GLP-1 concentrations. An optional paired 2-hour postprandial plasma glucose assessment may be performed at baseline and Day 180 in participants who voluntarily agree to this exploratory assessment. This test is not mandatory, is not a predefined primary or secondary endpoint, and is not a substitute for a standard oral glucose tolerance test. Interventions Eligible participants will be randomly assigned in a 1:1 ratio to one of the two treatment groups: atorvastatin plus UDCA or atorvastatin plus matching placebo. All participants will receive atorvastatin; only UDCA and its placebo will be administered under double-blind conditions. The intervention group will follow the oral administration regimen of atorvastatin at a dose of 20 mg (one tablet) once daily, plus UDCA at a dose of 500 mg (two tablets) once daily, with all medications taken at 8:00 pm. The control group will receive atorvastatin at an identical dose of 20 mg (one tablet) once daily, in combination with a 500 mg (two tablets) UDCA-matched placebo administered one time daily at the same time point. The use of other lipid-lowering agents will be strictly prohibited throughout the study period. Concomitant medication and lifestyle management All medications, procedures and relevant non-pharmacological treatments used within 3 months before randomisation and during follow-up will be recorded on the case report form. Particular attention will be paid to medications that may affect glucose metabolism, including systemic glucocorticoids, antipsychotics, immunosuppressants, high-dose thiazide diuretics and beta-blockers and to medications that may substantially affect atorvastatin exposure, especially strong CYP3A4 inhibitors or inducers such as itraconazole, clarithromycin, rifampicin and phenytoin. Unless clinically necessary, initiation of these medications during the trial will be discouraged. Clinically necessary use will be recorded, and sensitivity analyses will be considered. Participants will be advised to maintain their usual diet and physical activity throughout the study and to avoid initiating a new weight-loss programme or making major changes in exercise patterns. Body weight and body composition will be measured at scheduled visits, and important lifestyle changes that may influence glucose metabolism will be recorded. Eligibility criteria Inclusion criteria Aged 18–75 years. Aged 18–75 years. Fasting LDL-C level ≥3.4 mmol/L (130 mg/dL). Fasting LDL-C level ≥3.4 mmol/L (130 mg/dL). HbA1c level ≤6.0% (42 mmol/mol). HbA1c level ≤6.0% (42 mmol/mol). Willing and able to provide written informed consent. Willing and able to provide written informed consent. Exclusion criteria Prior or current diagnosis of type 1 or type 2 diabetes mellitus or prediabetes. (Participants with a single screening HbA1c value of 5.7%–6.0% were not excluded solely on this basis if they had no documented prior diagnosis of diabetes or pre-diabetes and did not meet diagnostic criteria for pre-diabetes on further clinical assessment.) Prior or current diagnosis of type 1 or type 2 diabetes mellitus or prediabetes. (Participants with a single screening HbA1c value of 5.7%–6.0% were not excluded solely on this basis if they had no documented prior diagnosis of diabetes or pre-diabetes and did not meet diagnostic criteria for pre-diabetes on further clinical assessment.) History of use or current use of any glucose-lowering medications. History of use or current use of any glucose-lowering medications. Use of statin therapy within 3 months prior to enrolment. Use of statin therapy within 3 months prior to enrolment. Concomitant use of three or more oral medications. (The criterion regarding concomitant oral medications was applied to reduce potential medication-related confounding, drug–drug interaction risk and adherence issues, as multiple regular oral medications may affect glucose metabolism or complicate assessment of the study intervention.) Concomitant use of three or more oral medications. (The criterion regarding concomitant oral medications was applied to reduce potential medication-related confounding, drug–drug interaction risk and adherence issues, as multiple regular oral medications may affect glucose metabolism or complicate assessment of the study intervention.) History of ASCVD, including prior myocardial infarction, acute coronary syndrome (within 1 year), stroke or transient ischaemic attack or symptomatic peripheral artery disease. History of ASCVD, including prior myocardial infarction, acute coronary syndrome (within 1 year), stroke or transient ischaemic attack or symptomatic peripheral artery disease. Presence of active liver disease, defined as any known infectious, malignant or metabolic aetiology, or unexplained elevation of ALT or AST>2 × upper limit of normal (ULN) at screening. Presence of active liver disease, defined as any known infectious, malignant or metabolic aetiology, or unexplained elevation of ALT or AST>2 × upper limit of normal (ULN) at screening. Uncontrolled hypertension, defined as systolic blood pressure ≥180 mm Hg or diastolic blood pressure ≥110 mm Hg despite antihypertensive therapy at the time of randomisation. Uncontrolled hypertension, defined as systolic blood pressure ≥180 mm Hg or diastolic blood pressure ≥110 mm Hg despite antihypertensive therapy at the time of randomisation. Estimated glomerular filtration rate (eGFR) ≤30 mL/min/1.73 m², calculated using the Chronic Kidney Disease Epidemiology Collaboration equation. Estimated glomerular filtration rate (eGFR) ≤30 mL/min/1.73 m², calculated using the Chronic Kidney Disease Epidemiology Collaboration equation. New York Heart Association class IV heart failure or known left ventricular ejection fraction <25%. New York Heart Association class IV heart failure or known left ventricular ejection fraction <25%. Clinically significant arrhythmia within 3 months prior to randomisation that remains uncontrolled despite medication or ablation therapy. Clinically significant arrhythmia within 3 months prior to randomisation that remains uncontrolled despite medication or ablation therapy. Acute or severe systemic infection; presence of haematologic, autoimmune or malignant diseases; severe psychiatric disorder or any other severe or unstable medical condition that may interfere with study participation. Acute or severe systemic infection; presence of haematologic, autoimmune or malignant diseases; severe psychiatric disorder or any other severe or unstable medical condition that may interfere with study participation. Planned surgical intervention within the next 6 months. Planned surgical intervention within the next 6 months. Pregnancy, lactation, intention to become pregnant or unwillingness to use effective contraception during the study period (for female participants of childbearing potential). Pregnancy, lactation, intention to become pregnant or unwillingness to use effective contraception during the study period (for female participants of childbearing potential). History of alcohol or substance use disorder within the past year. History of alcohol or substance use disorder within the past year. Secondary hypercholesterolaemia (eg, due to hypothyroidism or nephrotic syndrome). Secondary hypercholesterolaemia (eg, due to hypothyroidism or nephrotic syndrome). Known hypersensitivity to any study medication (atorvastatin or UDCA/placebo), their excipients or drugs of structurally related classes. Known hypersensitivity to any study medication (atorvastatin or UDCA/placebo), their excipients or drugs of structurally related classes. Documented history of homozygous familial hypercholesterolaemia. Documented history of homozygous familial hypercholesterolaemia. Concurrent participation in another clinical trial within the past 30 days or anticipated inability to complete the 6-month study period. Concurrent participation in another clinical trial within the past 30 days or anticipated inability to complete the 6-month study period. Any condition that, in the investigator’s judgement, may compromise patient safety or interfere with study compliance or outcome interpretation. Any condition that, in the investigator’s judgement, may compromise patient safety or interfere with study compliance or outcome interpretation. Treatment termination and withdrawal Study treatment may be discontinued if continuation is considered to compromise the participant’s safety or the validity of study evaluation. Reasons for discontinuation may include major protocol deviations, intolerable adverse events, use of prohibited medications, poor adherence or other circumstances judged by the investigator to require discontinuation. Participants may withdraw from the study at any time without giving a reason and without affecting their routine medical care. The reason for discontinuation will be documented. Adverse events An adverse event (AE) is defined as any unfavourable medical occurrence after administration of the study medication, regardless of its causal relationship with the study medication. All AEs will be recorded, including onset date, duration, severity, causality, actions taken and outcome. Appropriate medical management will be provided when necessary, and study treatment may be continued, interrupted or discontinued according to the investigator’s judgement. A SAE is defined as an event that results in death, is life-threatening, requires hospitalisation or prolongation of hospitalisation, results in persistent or significant disability/incapacity or causes a congenital anomaly or birth defect. All SAEs will be reported to the ethics committee in writing within 24 hours after the investigator becomes aware of the event and will be followed until resolution or stabilisation. Outcomes Primary outcome The primary outcome is the difference in HbA1c absolute change from baseline to Day 180 between the intervention and control groups. Secondary outcomes The secondary outcomes are the difference in the absolute change of cardiometabolic risk factors and body composition between the intervention and control groups from baseline to Day 180. Cardiometabolic risk factors include glycaemia-related parameters, lipid profile and other biomarkers. Glycaemia-related parameters include fasting glucose, fasting insulin, fasting C-peptide, HOMA-IR and fasting serum total GLP-1. A lipid profile includes total cholesterol, triglycerides, HDL-C, LDL-C and Lp(a). Other biomarkers include ALT, AST, CK and hs-CRP. Body composition includes body weight, body fat mass, muscle mass and visceral fat area. If available, 2-hour postprandial plasma glucose measurements at baseline and the final follow-up visit will be treated as exploratory. Safety SAEs, AEs, abnormal vital signs and abnormal laboratory parameters will be recorded and assessed from baseline to Day 180 to evaluate safety. Study drug The atorvastatin used in this study was manufactured and provided by Qilu Pharmaceutical Co., Ltd., Jinan, China. UDCA and its placebo are manufactured and provided by Wuhan Puyuan Pharmaceutical Co., Ltd., Wuhan, China. Atorvastatin will be provided as 20 mg, packaged in boxes of 14 tablets. UDCA and its matching placebo will be supplied as 250 mg, packaged in boxes of 24 tablets. Study medications will be dispensed at baseline in sufficient quantity to last until the first follow-up visit at Day 40. At each scheduled visit (Days 40 and 110), unused medication from the previous period will be collected for accountability, and the subsequent supply of study drugs will be dispensed. At the final visit (Day 180), only medication collection will be performed without dispensing new study drugs. Drug dispensing and packaging will be performed by an independent physician through the pharmacy of the First Affiliated Hospital of Xi'an Jiaotong University. Blinding This study is a double-blind, randomised controlled trial. Participants, investigational staff, outcome assessors and the clinical study team will remain blinded to group allocation throughout the trial. An independent physician, not otherwise involved in the study, will be responsible for managing emergency unblinding if required for medical reasons. Blinding will be maintained at the packaging stage. The UDCA tablets and placebo tablets will be identical in appearance, colour, odour and packaging, differing only by a unique randomisation number. The allocation sequence linking the randomisation numbers to the treatment assignments (ie, the trial code) will be securely held by the independent manufacturer and will not be disclosed to the investigators or participants. Participants will be assigned to treatment groups based on the randomisation schedule and will be dispensed medication according to their assigned number. Consequently, neither the participants nor the investigators will be aware of the specific treatment received, ensuring the integrity of the double-blind procedure throughout the study period. Randomisation Randomisation will be performed using the Research Electronic Data Capture (REDCap) system immediately after eligibility confirmation and completion of the informed consent process. The randomisation sequence will be generated by an independent statistician using a permuted block randomisation method (block size=4) to ensure allocation concealment and balance between groups. Eligible participants will be randomly assigned in a 1:1 ratio to either the atorvastatin combined with UDCA group or the atorvastatin combined with a matching placebo group. Each randomisation number corresponds to a specific investigational product (either UDCA or placebo), which has been pre-packaged and labelled by the manufacturer. Following randomisation, the REDCap system will display the assigned treatment number. Participants will then receive the medication package corresponding to that specific number. This web-based allocation procedure ensures that the investigational staff remains blinded to the treatment assignment until the medication is dispensed. Sample size Based on the net 8-week reduction observed in the UDCA versus control group in the trial,14 we assumed an SD of 0.60% and a true treatment effect of 0.4%. Under these assumptions, 51 participants per group were estimated to provide at least 80% power with alpha=0.05 and 1:1 randomisation. However, to account for a 20% dropout rate, a total sample size of 128 was selected (64 for each group). Sample size calculations were performed using PASS software V.21.0 (NCSS, LLC, Kaysville, UT, USA). Statistical analysis Baseline characteristics between the intervention and control groups will be compared. Continuous variables with a normal distribution will be expressed as mean±SD; otherwise, they will be expressed as median (IQR). Categorical variables will be expressed as frequencies and percentages. The primary and secondary analyses will be performed in the intention-to-treat (ITT) population, which includes all participants who provide informed consent and undergo randomisation. A mixed model for repeated measures will be used to analyse the difference in primary and secondary outcomes from baseline to Day 180. The model will include treatment group, visit time and their interaction as fixed effects, with the corresponding baseline data included as a covariate. For each outcome, model assumptions will be tested, and variable transformation will be considered if necessary to satisfy the assumptions. For the primary outcome, clinically relevant covariates, including age and sex, will also be included in the model to reduce their potential influence on the interpretation. A p value of <0.05 will be considered significant. Missing outcome data will be handled within the mixed-model framework under the assumption that data are missing at random. If the extent or pattern of missing data raises concern, multiple imputation or other sensitivity analyses will be considered. Where pairwise comparisons across multiple visits or groups are conducted, appropriate multiplicity adjustment, including Tukey adjustment when applicable, will be used. A sensitivity analysis will be performed in the per-protocol (PP) population to assess the robustness of the primary finding under conditions of adequate protocol adherence. The PP population will include participants who completed the primary outcome assessment, had no major protocol deviations, did not use prohibited medications and achieved the prespecified level of adherence to the study medication, defined as at least 80%. Subgroup analyses will be conducted to examine the consistency of treatment effects across the following subgroups: sex (male vs female), age (grouped by median age), baseline HbA1c (<5.7% vs 5.7–6.0%) and BMI (<28 vs ≥28 kg/m²). For all subgroup analyses, interaction tests will be used to assess whether treatment effects differ between subgroups and will be interpreted as exploratory. Patient and public involvement Patients or the public were not involved in the design, conduct, reporting or dissemination plans of this study. Discussion The increasing global burden of ASCVD has led to the widespread use of statins in clinical practice. Although robust evidence supports the role of statins in secondary prevention,19 their use in primary prevention has received less attention, particularly regarding metabolic consequences.20 A critical consideration in the primary prevention of ASCVD with statin therapy is the associated risk of dysglycaemia, which encompasses impaired glucose tolerance and new-onset type 2 diabetes.8 14 Statin-associated dysglycaemia is a multifactorial process involving both impaired insulin sensitivity and impaired pancreatic β-cell insulin secretory function. Cederberg et al reported that statin treatment was associated with a 24% reduction in insulin sensitivity and a 12% reduction in insulin secretion.21 More recently, Zhang et al suggested that atorvastatin may affect pancreatic β-cell function and glucose-stimulated insulin secretion by enhancing LDLR-mediated LDL-C uptake and regulating PCSK9 expression.22 In parallel, our previous findings suggested that statin-induced glucose intolerance may be associated with insulin resistance.14 Accumulating evidence indicates that statin use is associated with a 40% increase in the risk of incident diabetes compared with nonusers, and this risk exhibits a duration-dependent escalation: hazard ratios (HRs) rise from 1.36 for 1–5 years of use, to 1.41 for 6–10 years, 1.60 for 11–15 years and reach 1.76 for≥16 years of use.23 This metabolic adverse effect frequently contributes to poor medication adherence and hesitancy to initiate therapy among high-risk individuals,24 which may increase the risk of major adverse cardiovascular events.25 26 Nevertheless, the cardiovascular benefits of statins in primary prevention remain substantial. A Danish cohort study demonstrated that among adults without clinical cardiovascular disease, high adherence to statin therapy was associated with a 1.76% absolute reduction in the 5-year risk of major adverse cardiovascular events compared with those with low adherence,27 underscoring the vital role of statins in primary prevention. Therefore, optimising the balance between the cardiovascular benefits and glycaemic risks of statin therapy represents a significant challenge in contemporary cardiovascular risk management. This protocol aims to evaluate a novel strategy to mitigate statin-associated dysglycaemia while preserving the cardioprotective efficacy of statin therapy. In this study, we propose a novel strategy to address this gap: combining atorvastatin with UDCA in statin-naïve patients at moderate- to high-ASCVD risk without prior cardiovascular events. This approach aims to preserve the cardioprotective benefits of statins while attenuating their adverse glycaemic effects, thereby optimising the risk-benefit profile of statin therapy in primary prevention. If effective, this regimen could offer a new therapeutic paradigm for statin-induced adverse events. A key innovation of our trial is the evaluation of a UDCA-based strategy to mitigate dysglycaemia specifically in a primary prevention cohort, a demographic that has been under-represented in prior statin adjunctive therapy research. Moreover, while UDCA is traditionally used for hepatobiliary disorders, its repurposing for mitigating statin-related dysglycaemia is novel. Preliminary data from our pilot study suggest that UDCA supplementation significantly improves HbA1c levels in long-term statin users.14 However, the role and efficacy of UDCA as an adjunct to statin therapy in primary prevention remain uncertain and require further investigation. Beyond conventional glycaemic metrics (glucose and HbA1c), we will also assess insulin sensitivity, GLP-1 levels and body composition changes. These measures may provide exploratory information regarding metabolic pathways potentially affected by UDCA. Limitations This study has several limitations. First, it is a single-centre trial with a modest sample size, which may limit generalisability and reduce statistical power for subgroup analyses. Second, because standard OGTT, mixed-meal tolerance testing and serial insulin or GLP-1 measurements would have increased participant burden and might have adversely affected recruitment and follow-up adherence, these assessments were not mandatory. Although HbA1c was selected as the primary outcome for feasibility, it may be less sensitive than dynamic metabolic testing for detecting early dysglycaemic changes after statin initiation.28 Third, HOMA-IR and fasting GLP-1 are fasting markers and cannot definitively distinguish insulin secretion, insulin sensitivity and incretin dynamics. In addition, GLP-1 will be assessed as fasting serum total GLP-1 rather than plasma active GLP-1 or dynamic postprandial GLP-1 responses. Therefore, GLP-1-related findings should be interpreted cautiously as exploratory biomarkers and may not be directly comparable with studies measuring plasma active GLP-1 or dynamic postprandial GLP-1 responses. Finally, dietary intake and physical activity will not be strictly controlled, although participants will be advised to maintain their usual lifestyle, and body composition will be monitored during follow-up. Ethics and dissemination Ethics This study was approved by the Clinical Research Ethics Committee of the First Affiliated Hospital of Xi’an Jiaotong University (No. XJTU1AF2023LSK-149-02). This trial will be conducted in accordance with the principles of the Declaration of Helsinki and is registered at the US National Institutes of Health (ClinicalTrials.gov identifier NCT06684106). The contact email address of the Ethics Committee is xjyfyllh@163.com. Dissemination We will disseminate the findings of the study through multiple channels, including publication in academic journals and presentation at multiple conferences. We will make concerted efforts to ensure the wide dissemination of this research. Current status Trial recruitment began in November 2024 and is ongoing. Trial follow-up is expected to be completed in 2026. Supplementary material Footnotes Funding: This work was supported by a grant from the Clinical Research Special Fund of the Chinese Society of Cardiology (CSCF2022B04). Prepublication history and additional supplemental material for this paper are available online. To view these files, please visit the journal online (https://doi.org/10.1136/bmjopen-2026-117417) Provenance and peer review: Not commissioned; externally peer reviewed. Patient consent for publication: Not applicable. Patient and public involvement: Patients and/or the public were not involved in the design, or conduct, or reporting, or dissemination plans of this research. References Supplementary Materials